Updated labeling for menopausal hormone therapy
JAMA
About The Article: This Viewpoint describes the U.S. Food and Drug Administration’s intended label updates and removal of black box warnings for menopausal hormone therapy based on current evidence.
Corresponding Author: To contact the corresponding author, Martin A. Makary, MD, MPH, email commissionersoffice@fda.hhs.gov.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.22259)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.22259?guestAccessKey=c130264b-10d4-408c-9685-81edb5a22279&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111025
END
Corresponding Author: To contact the corresponding author, Martin A. Makary, MD, MPH, email commissionersoffice@fda.hhs.gov.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.22259)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.22259?guestAccessKey=c130264b-10d4-408c-9685-81edb5a22279&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111025
END